Publications by authors named "Lars Bauer"

Claim this Profile
C
Comparison of established and preliminarily proposed ASAS MRI working group cut-offs for inflammatory MRI lesions in the sacroiliac joints in radiographic and non-radiographic axial spondyloarthritis.
Xenofon Baraliakos, Pedro M Machado, Lars Bauer, Bengt Hoepken, Mindy Kim

RMD Open· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploratory analysis of the potential disconnect between objective inflammatory response and clinical response following certolizumab pegol treatment in patients with active axial spondyloarthritis.
Martin Rudwaleit, Helena Marzo-Ortega, Victoria Navarro-Compán, Rachel Tham, Thomas Kumke, Lars Bauer

RMD Open· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term clinical outcomes of certolizumab pegol treatment in non-radiographic axial spondyloarthritis stratified by baseline MRI and CRP status.
Martin Rudwaleit, Atul Deodhar, Lars Bauer, Lianne Gensler, Bengt Hoepken

RMD Open· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Certolizumab Pegol Treatment in Patients with Axial-Spondyloarthritis-Associated Acute Anterior Uveitis: a Narrative Review.
Irene E van der Horst-Bruinsma, Philip C Robinson, Ennio G Favalli, Frank D Verbraak, Mindy Kim, Lars Bauer

Rheumatol Ther· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Certolizumab Pegol Efficacy in Patients With Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status: An Analysis From the C-axSpAnd Study.
Philip C Robinson, Walter P Maksymowych, Lianne S Gensler, Stephen Hall, Martin Rudwaleit, Lars Bauer

ACR Open Rheumatol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study.
Désirée van der Heijde, Lianne S Gensler, Walter P Maksymowych, Robert Landewé, Martin Rudwaleit, Lars Bauer

RMD Open· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and Safety of Certolizumab Pegol in Axial Spondyloarthritis in a Real-World Setting in Greece: A Sub-Analysis of the Prospective Non-Interventional CIMAX Cohort Study.
Gkikas Katsifis, Athina Theodoridou, Andreas Bounas, Panagiotis Georgiou, Petros Sfikakis, Lars Bauer

Mediterr J Rheumatol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol.
Walter P Maksymowych, Thomas Kumke, Simone E Auteri, Bengt Hoepken, Lars Bauer

Arthritis Res Ther· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW study.
Irene E van der Horst-Bruinsma, Rianne E van Bentum, Frank D Verbraak, Atul Deodhar, Thomas Rath, Lars Bauer

Ther Adv Musculoskelet Dis· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and safety of 12-month certolizumab pegol treatment for axial spondyloarthritis in real-world clinical practice in Europe.
Xenofon Baraliakos, Torsten Witte, Luc De Clerck, Bruno Frediani, Eduardo Collantes-Estévez, Lars Bauer

Rheumatology (Oxford)· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE.
Robert Landewé, Désirée van der Heijde, Maxime Dougados, Xenofon Baraliakos, Filip Van den Bosch, Lars Bauer

Rheumatol Ther· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction.
Robert Bm Landewé, Désirée van der Heijde, Maxime Dougados, Xenofon Baraliakos, Filip E Van den Bosch, Lars Bauer

Ann Rheum Dis· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW.
Irene van der Horst-Bruinsma, Rianne van Bentum, Frank D Verbraak, Thomas Rath, James T Rosenbaum, Lars Bauer

RMD Open· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis.
Atul Deodhar, Lianne S Gensler, Jonathan Kay, Walter P Maksymowych, Nigil Haroon, Lars Bauer

Arthritis Rheumatol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, double-blind, crossover study of the adhesiveness of two formulations of rotigotine transdermal patch in patients with Parkinson's disease.
Jan-Peer Elshoff, Lars Bauer, Nadine Goldammer, Marga Oortgiesen, Hanna Pesch

Curr Med Res Opin· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, Tolerability, and Bioequivalence of Two Formulations of Rotigotine in Healthy Chinese Subjects.
Yun Liu, Brian Tomlinson, Jiyuan Guo, Mahnaz Asgharnejad, Lars Bauer

Clin Ther· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An observational study of rotigotine transdermal patch and other currently prescribed therapies in patients with Parkinson's disease.
Thomas Müller, Eduardo Tolosa, Letitia Badea, Mahnaz Asgharnejad, Frank Grieger, Lars Bauer

J Neural Transm (Vienna)· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial.
Désirée van der Heijde, Xenofon Baraliakos, Kay-Geert A Hermann, Robert B M Landewé, Pedro M Machado, Lars Bauer

Ann Rheum Dis· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
4
4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis.
Désirée van der Heijde, Atul Deodhar, Oliver FitzGerald, Roy Fleischmann, Dafna Gladman, Lars Bauer

RMD Open· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rotigotine transdermal patch in Chinese patients with advanced Parkinson's disease: A randomized, double-blind, placebo-controlled pivotal study.
Zhen-Xin Zhang, Chun-Feng Liu, En-Xiang Tao, Ming Shao, Yi-Ming Liu, Lars Bauer

Parkinsonism Relat Disord· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
Désirée van der Heijde, Maxime Dougados, Robert Landewé, Joachim Sieper, Walter P Maksymowych, Lars Bauer

Rheumatology (Oxford)· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switching from an oral dopamine receptor agonist to rotigotine transdermal patch: a review of clinical data with a focus on patient perspective.
Sun Ju Chung, Mahnaz Asgharnejad, Lars Bauer, Arturo Benitez, Babak Boroojerdi

Expert Rev Neurother· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Rotigotine transdermal patch in Chinese patients with early Parkinson's disease: A randomized, double-blind, placebo-controlled pivotal study" [Park. Relat. Disord. 28 (2016) 49-55].
Zhen-Xin Zhang, Hui-Fang Shang, Xingyue Hu, Shengdi Chen, Zhongxin Zhao, Lars Bauer

Parkinsonism Relat Disord· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patients' perception of Parkinson's disease-associated pain following initiation of rotigotine: a multicenter non-interventional study.
Lars Timmermann, Christian Oehlwein, Gerhard Ransmayr, Holger Fröhlich, Edgar Will, Lars Bauer

Postgrad Med· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Rotigotine at Different Stages of Parkinson's Disease Symptom Severity and Disability: A Post Hoc Analysis According to Baseline Hoehn and Yahr Stage.
Nir Giladi, Anthony P Nicholas, Mahnaz Asgharnejad, Elisabeth Dohin, Franz Woltering, Lars Bauer

J Parkinsons Dis· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis